Kura Oncology (KURA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.77
- Estimate
- -$0.88
- Surprise
- +12.1%
- Revenue (period 2026-06-30)
- $20.9M
- Score today
- 4.3/10
Revenue source: xbrl.
How the report landed
Kura Oncology (KURA) reported a narrower loss than forecast — adjusted EPS of -$0.77 against the -$0.88 estimate (a 12.1% beat on a still-unprofitable quarter).
Coverage in the report window
- Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday — benzinga, 2026-08-13
- Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38 — benzinga, 2026-08-13
- Kura Oncology Q2 EPS $(0.77) Beats $(0.87) Estimate, Sales $20.874M Miss $21.420M Estimate — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates KURA Sell at 4.3/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +12.1% surprise compares with a -53.4% four-quarter average. Next scheduled report: 2027-03-11.
What argues against it
- Concentration risk — Product: KOMZIFTI
- DATA_ISSUE: analyst_target_implausible (raw $32.00 vs price $7.09 — ratio 4.5×). Rejected, falling back to technical TP.
- Quality below floor (2.8 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.09
- Price target
- $10.74
- Stop
- $6.59
- Upside to target
- +51.5%
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
KURA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $713.9M
- P/E (fwd)
- -3.2
- 52-week range
- $6.75–$13.90
- Off 52-week high
- 49.0%
- RSI (14)
- 30
- Volume vs avg
- 1.10×
- Score today
- 4.3/10